Literature DB >> 31371806

Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature.

Yang Li1,2, Jake Maule2, Jadee L Neff2, Chad M McCall2, Sarah Rapisardo2, Anand S Lagoo2, Lian-He Yang3, Regina D Crawford4, Yue Zhao5,6, Endi Wang7.   

Abstract

Myeloid neoplasms occasionally occur in patients with sickle cell disease, and the underlying connection between the two diseases is unclear. Herein, we retrospectively analyzed four cases of sickle cell disease patients who developed myeloid neoplasm. Age at time of diagnosis ranged from 27 to 59 years with a median of 35.5 years. Two patients were treated with hydroxyurea and the other two with supportive care alone, with one out of the four patients receiving additional treatment with hematopoietic stem cell transplant. Three patients presented with leukocytosis, and the remaining patient presented with pancytopenia. Two patients were diagnosed with myelodysplastic syndrome/myeloproliferative neoplasm, one with myelodysplastic syndrome, and the other with acute myeloid leukemia. All four cases demonstrated certain degrees of myelodysplasia and complex cytogenetic abnormalities with - 7/7q- and/or - 5/5q- or with 11q23 (KMT2A) rearrangement. This cytogenetic profile resembles that seen in therapy-related myeloid neoplasm, suggesting that myeloid neoplasm in the setting of sickle cell disease may represent a subcategory of the disease distinct from de novo myeloid neoplasm in general. Extensive literature review further demonstrates this similarity in cytogenetic profile, as well as in other associated pathologic features. Potential etiology includes therapy for sickle cell disease, disease-related immunomodulation, or disease-related chronic inflammation. We hypothesize that constant hematopoietic hyperplasia, stimulated by a hemolysis-induced cytokine storm, may increase the chance of somatic mutations/cytogenetic aberrations, resulting in transformation of myeloid precursors. This group of myeloid neoplasms seems to herald a dismal clinical outcome, with median survival <1 year, although the exact pathogenesis and biology of the disease remain to be investigated by large cohorts in future studies.

Entities:  

Year:  2019        PMID: 31371806     DOI: 10.1038/s41379-019-0325-6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  14 in total

1.  Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.

Authors:  Jack Y Ghannam; Xin Xu; Irina Maric; Laura Dillon; Yuesheng Li; Matthew M Hsieh; Christopher S Hourigan; Courtney D Fitzhugh
Journal:  Blood       Date:  2020-04-02       Impact factor: 22.113

2.  Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?

Authors:  Marilyn J Telen
Journal:  Blood Adv       Date:  2020-07-28

3.  Gene therapy for sickle cell disease: where we are now?

Authors:  Julie Kanter; Corey Falcon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 4.  Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.

Authors:  Tolulope O Rosanwo; Daniel E Bauer
Journal:  Mol Ther       Date:  2021-10-08       Impact factor: 11.454

5.  Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.

Authors:  Farid Boulad; Aurelio Maggio; Xiuyan Wang; Paolo Moi; Santina Acuto; Friederike Kogel; Chayamon Takpradit; Susan Prockop; Jorge Mansilla-Soto; Annalisa Cabriolu; Ashlesha Odak; Jinrong Qu; Keyur Thummar; Fang Du; Lingbo Shen; Simona Raso; Rita Barone; Rosario Di Maggio; Lorella Pitrolo; Antonino Giambona; Maura Mingoia; John K Everett; Pascha Hokama; Aoife M Roche; Vito Adrian Cantu; Hriju Adhikari; Shantan Reddy; Eric Bouhassira; Narla Mohandas; Frederic D Bushman; Isabelle Rivière; Michel Sadelain
Journal:  Nat Med       Date:  2022-01-03       Impact factor: 87.241

6.  A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease.

Authors:  Alexis Leonard; John F Tisdale
Journal:  Mol Ther       Date:  2021-03-19       Impact factor: 11.454

7.  American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.

Authors:  Julie Kanter; Robert I Liem; Françoise Bernaudin; Javier Bolaños-Meade; Courtney D Fitzhugh; Jane S Hankins; M Hassan Murad; Julie A Panepinto; Damiano Rondelli; Shalini Shenoy; John Wagner; Mark C Walters; Teonna Woolford; Joerg J Meerpohl; John Tisdale
Journal:  Blood Adv       Date:  2021-09-28

8.  Clonal hematopoiesis in sickle cell disease.

Authors:  Thomas Pincez; Simon S K Lee; Yann Ilboudo; Michael Preuss; Anne-Laure Pham Hung d'Alexandry d'Orengiani; Pablo Bartolucci; Frédéric Galactéros; Philippe Joly; Daniel E Bauer; Ruth J F Loos; R Coleman Lindsley; Guillaume Lettre
Journal:  Blood       Date:  2021-11-25       Impact factor: 25.476

Review 9.  Immuno-Modulation of Hematopoietic Stem and Progenitor Cells in Inflammation.

Authors:  Maiko Sezaki; Yoshikazu Hayashi; Yuxin Wang; Alban Johansson; Terumasa Umemoto; Hitoshi Takizawa
Journal:  Front Immunol       Date:  2020-11-24       Impact factor: 7.561

10.  Acute leukemia in sickle cell disease patients in a tertiary health facility in Nigeria: a case series.

Authors:  Oladapo W Aworanti; Foluke A Fasola; Taiwo R Kotila; John A Olaniyi; Biobele J Brown
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.